Spero Therapeutics (NASDAQ:SPRO) was upgraded by analysts at TheStreet from a “d” rating to a “c-” rating in a research note issued to investors on Tuesday, TheStreetRatingsTable reports.
Several other equities research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, March 15th. Finally, Oppenheimer set a $30.00 price objective on shares of Spero Therapeutics and gave the company a “buy” rating in a research report on Tuesday, February 26th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Spero Therapeutics presently has an average rating of “Hold” and an average price target of $20.25.
SPRO stock opened at $12.82 on Tuesday. Spero Therapeutics has a 12 month low of $5.52 and a 12 month high of $18.23. The company has a debt-to-equity ratio of 0.04, a quick ratio of 17.48 and a current ratio of 17.48. The business’s 50-day moving average price is $11.82. The stock has a market cap of $236.75 million, a PE ratio of -4.93 and a beta of 2.34.
A number of institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP acquired a new position in Spero Therapeutics in the 1st quarter valued at about $39,000. Virtu Financial LLC acquired a new position in Spero Therapeutics in the 1st quarter valued at about $134,000. IHT Wealth Management LLC acquired a new position in Spero Therapeutics in the 4th quarter valued at about $115,000. Bank of America Corp DE raised its stake in Spero Therapeutics by 2,036.1% in the 4th quarter. Bank of America Corp DE now owns 83,009 shares of the company’s stock valued at $510,000 after purchasing an additional 79,123 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new position in Spero Therapeutics in the 4th quarter valued at about $169,000. 46.70% of the stock is owned by institutional investors.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Recommended Story: What is meant by holder of record?
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.